Oyster Point Pharma announced that William J. Link, PhD, is retiring from Oyster Point’s Board of Directors, effective as of March 17, 2022. Dr. Link will continue to serve as a consultant to the company.

“On behalf of the entire Oyster Point organization, we are eternally thankful to Dr. Link for his leadership and significant contributions over the years,” said Jeffrey Nau, MMS, PhD, president and chief executive officer, Oyster Point Pharma. “Even in his retirement, he will be contributing through our shared goal of elevating the standard of care for people suffering with ophthalmic diseases.”

Dr. Link joined Oyster Point’s Board of Directors at the inception of the company in July 2015 and was a member of the compensation committee. He continued his service through the company’s successful transition from private to public biopharmaceutical company, through the launch of Tyrvaya (varenicline solution) Nasal Spray and the evolution of a promising pipeline with potentially transformative investigational therapies in a range of ocular surface diseases.

"It has been an honor to serve on Oyster Point’s Board during this exciting time of transformation and growth," said Dr. Link. "As a shareholder and consultant, I remain steadfast in my belief in Oyster Point’s leadership team and innovative portfolio as the company continues its next phase of continued growth and shareholder value creation strategy."